One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Biopsy-driven trial a milestone towards precision medicine in RA
Sarah Onuora
doi : 10.1038/s41584-021-00599-x
Volume 17, Issue 4, April 2021, Published 10 March 2021
Antidepressant identified as potential DMOAD
Jessica McHugh
doi : 10.1038/s41584-021-00594-2
Volume 17, Issue 4, April 2021, Published 04 March 2021
RA remission attainable during pregnancy
Jessica McHugh
doi : 10.1038/s41584-021-00595-1
Volume 17, Issue 4, April 2021, Published 04 March 2021
2019 EULAR–ACR classification criteria for SLE performs well in children
Jessica McHugh
doi : 10.1038/s41584-021-00596-0
Volume 17, Issue 4, April 2021, Published 05 March 2021
Tocilizumab prevents ILD progression in early SSc
Jessica McHugh
doi : 10.1038/s41584-021-00597-z
Volume 17, Issue 4, April 2021, Published 05 March 2021
Different phenotypes identified for Behçet syndrome
Jessica McHugh
doi : 10.1038/s41584-021-00587-1
Volume 17, Issue 4, April 2021, Published 22 February 2021
Cigarette smoke exacerbates joint damage via miR-132
Joanna Clarke
doi : 10.1038/s41584-021-00586-2
Volume 17, Issue 4, April 2021, Published 15 February 2021
Targeting pDCs in SSc
Sarah Onuora
doi : 10.1038/s41584-021-00598-y
Volume 17, Issue 4, April 2021, Published 08 March 2021
How do dietary interventions affect serum urate and gout?
Sarah L. Morgan & Jasvinder A. Singh
doi : 10.1038/s41584-021-00576-4
Volume 17, Issue 4, April 2021, Published 28 January 2021
An important question for patients and providers is whether and to what extent dietary interventions, diet supplements or weight loss can help to prevent incident gout or manage existing gout. Evidence is emerging, but randomized trials are still needed to fill this important knowledge gap.
Moving towards a molecular categorization of autoimmune disease
Michael L. Whitfield
doi : 10.1038/s41584-021-00589-z
Volume 17, Issue 4, April 2021, Published 02 March 2021
The field of rheumatology is poised to categorize the phenotypes of systemic autoimmune diseases on the basis of measurable and quantifiable molecular signatures. Emerging efforts to identify similarities across diseases, predict clinical outcomes and predict response to therapy using quantitative, data-driven approaches could considerably change treatment paradigms.
Location, location, location: how the tissue microenvironment affects inflammation in RA
Christopher D. Buckley, Caroline Ospelt, Steffen Gay & Kim S. Midwood
doi : 10.1038/s41584-020-00570-2
Volume 17, Issue 4, April 2021, Published 01 February 2021
Tissues are composed of cells and an extracellular matrix. In this Review, the authors discuss how a greater understanding of the role of the synovial extracellular matrix in rheumatoid arthritis could lead to improved disease diagnosis and new therapies.
TNF in the era of immune checkpoint inhibitors: friend or foe?
Allen Y. Chen, Jedd D. Wolchok & Anne R. Bass
doi : 10.1038/s41584-021-00584-4
Volume 17, Issue 4, April 2021, Published 08 March 2021
TNF inhibitors are used to treat various immune-related adverse events caused by immune checkpoint inhibitors (ICIs). However, whether TNF inhibition compromises the anticancer efficacy of ICI therapy is unknown. This Review discusses the relationship between TNF, TNF inhibition and cancer.
The gut–joint axis in rheumatoid arthritis
Mario M. Zaiss, Hsin-Jung Joyce Wu, Daniele Mauro, Georg Schett & Francesco Ciccia
doi : 10.1038/s41584-021-00585-3
Volume 17, Issue 4, April 2021, Published 05 March 2021
Intestinal dysbiosis is thought to be involved in the early stages of rheumatoid arthritis (RA). In this Review, the authors discuss the gut–joint axis in RA and the potentially pathogenic role of gut-derived immune cells in the joints.
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
Lourdes M. Perez-Chada, Rebecca H. Haberman, Vinod Chandran, Cheryl F. Rosen, Christopher Ritchlin, Lihi Eder, Philip Mease, Soumya Reddy, Alexis Ogdie, Joseph F. Merola & Jose U. Scher
doi : 10.1038/s41584-021-00578-2
Volume 17, Issue 4, April 2021, Published 15 February 2021
In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies.
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis
Alessandro Granito, Luigi Muratori, Francesco Tovoli & Paolo Muratori
doi : 10.1038/s41584-021-00573-7
Volume 17, Issue 4, April 2021, Published 18 January 2021
Reply to: Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis
David S. Pisetsky & Peter E. Lipsky
doi : 10.1038/s41584-021-00574-6
Volume 17, Issue 4, April 2021, Published 18 January 2021
Author Correction: Raynaud phenomenon and digital ulcers in systemic sclerosis
Michael Hughes, Yannick Allanore, Lorinda Chung, John D. Pauling, Christopher P. Denton & Marco Matucci-Cerinic
doi : 10.1038/s41584-021-00591-5
Volume 17, Issue 4, April 2021, Published 09 March 2021
Author Correction: Location, location, location: how the tissue microenvironment affects inflammation in RA
Christopher D. Buckley, Caroline Ospelt, Steffen Gay & Kim S. Midwood
doi : 10.1038/s41584-021-00602-5
Volume 17, Issue 4, April 2021, Published 12 March 2021
